Letters

Correspondance

Ovarian cancer screening

Usha Menon’s review of ovarian cancer screening appears to misquote the result of the randomized controlled trial of multimodal screening (with the tumour marker CA125 and ultrasonography) by Jacobs and associates.

In that study the number of deaths from ovarian cancer was 18 among the 10 977 patients in the control group and 9 among the 10 958 patients in the screened group (relative risk of death in the unscreened group 2.0, 95% confidence interval 0.78–5.13); Menon’s article seems to state the reverse. Although the difference in number of deaths was not statistically significant, these results represent a possible halving of the death rate by screening, rather than a possible doubling.

Erica L. Eason
Associate Professor
Obstetrics and Gynaecology
University of Ottawa
Ottawa, Ont.

References
DOI:10.1503/cmaj.1041601

Treating C. difficile

In their review of Clostridium difficile-associated diarrhea, Susan Poutanen and Andrew Simor note that concurrent administration of probiotic agents (e.g., Saccharomyces boulardii and Lactobacillus GG) and antibiotics to prevent recurrence of the problem has yielded mixed results.

There is substantial overlap among antibiotic use, C. difficile colonization and subsequent C. difficile-induced diarrhea. In fact, 26% to 50% of antibiotic-associated diarrhea can be attributed to C. difficile. A meta-analysis of S. boulardii and Lactobacillus GG co-administered with antibiotics (including the antibiotics regarded as the most common inducers of diarrhea [ampicillin, cephalosporins, clindamycin]) for treatment of antibiotic-associated diarrhea in a diverse population (881 patients of all ages, including inpatients, outpatients and people from developing countries) provided strong evidence to suggest that probiotic agents prevent antibiotic-associated diarrhea (relative risk 0.40, 95% confidence interval [CI] 0.28–0.57). A larger meta-analysis of 1380 patients of 7 probiotic species administered with a host of antibiotics provided further evidence of the effectiveness of probiotics for the prevention of antibiotic-associated diarrhea (odds ratio 0.37, 95% CI 0.26–0.53).

However, these meta-analyses are limited, in that they provided little information about the species and doses that would yield the most beneficial results and did not identify the patient population(s) that would benefit most. In addition, neither author group performed a meta-analysis for adverse events, nor did they comment on why such an analysis was not done. We might assume that only minor adverse events were reported in the randomized controlled trials reviewed; however, meta-analyses of such trials often overlook important details. Although no adverse events were reported in these meta-analyses, infections resulting from probiotic use (e.g., bacteremia, endocarditis, septicemia, pneumonia and deep abdominal abscesses) have been reported in neonates and severely debilitated and immunocompromised individuals. It is unclear, however, whether exogenous or endogenous Lactobacilli were the cause of the few cases of Lactobacillus bacteremia that have been reported.

The public health burden of this problem is substantial and the preliminary evidence promising; as such, concurrent use of probiotics with antibiotics in the hospital setting is worth further consideration. However, a research agenda is needed to determine which probiotic species and dosages might provide effective prophylaxis and which hospital population(s) would benefit most.

Bradley C. Johnston
Graduate Student
Sunita Vohra
Director, Complementary and Alternative Research and Education (CARE) Program
Department of Pediatrics
University of Alberta
Edmonton, Alta.

References
In their comprehensive review of Clostridium difficile-associated diarrhea (CDAD), Susan Poutanen and Andrew Simor refer to the use of anion-binding resins (colestipol or cholestyramine). It is important to highlight the timing of administration of these agents in relation to other oral therapeutic agents (metronidazole or vancomycin). In addition to binding the toxin and spores of C. difficile, the binding agents may also bind orally administered therapeutic agents to various degrees, thereby negating their effect. Ideally, resin binders should be given either an hour before or 4 to 6 hours after administration of the oral antibiotics to avoid this problem. However, in clinical practice, especially in hospitals, I have found that the binders and other agents are often given simultaneously; many of the patients have recurrent disease, are described as being resistant to metronidazole (an otherwise rare situation) and are subsequently given oral vancomycin, which is more costly. I believe that this is a common cause of iatrogenic resistance to oral metronidazole.

There are no studies of this phenomenon (i.e., no evidence in this era of evidenced-based and “evidence-made” medicine), but on the basis of a theoretical understanding of the pathophysiology of CDAD, I often administer 10 to 14 days of oral metronidazole followed by 5 to 7 days of oral cholestyramine (to bind the remaining spores in the gut) and have observed a very low rate of recurrence. It is time to prospectively evaluate this simple strategy of sequential therapy in the management of CDAD in a randomized trial.

Malvinder S. Parmar
Associate Professor, Medicine
Northern Ontario School of Medicine
Laurentian and Lakehead Universities
Sudbury and Thunder Bay, Ont.

We agree with Malvinder Parmar that the role of anion-binding resins in the treatment of CDAD needs to be studied further. Anion-binding resins, such as cholestyramine and colestipol, have been shown to bind C. difficile toxins and have consequently been proposed as potentially useful in the treatment of CDAD, as we mentioned in our review. Parmar also suggests that anion-binding resins may also bind C. difficile spores, but to the best of our knowledge, this phenomenon has not been described in published reports. Small numbers of mostly anecdotal reports of success and failure with the use of anion-binding resins in the treatment of CDAD have been published (summarized by Ariano and associates), but no large randomized controlled trials have been completed to definitively determine the role of resins. Anion-binding resins have been shown to bind vancomycin and theoretically may bind other antibiotics such as metronidazole, although we are not aware of any published data specifically describing this. Given the possibility of antibiotic binding by resins, some authors have suggested not using anion-binding resins in the treatment of CDAD, whereas others recommend using them only if administered at different times from metronidazole or vancomycin. As Parmar suggests, more study is needed to address the optimal indication and timing of anion-binding resins in the treatment of CDAD.

Susan M. Poutanen
Andrew E. Simor

Department of Laboratory Medicine and Pathobiology
University of Toronto
Toronto, Ont.

References

[The authors respond to Dr. Parmar:]

Emmanuel Andrés and colleagues, in their comprehensive review of diagnosis and treatment of vitamin B₁₂ (cobalamin) deficiency, fail to consider 2 elements relevant to the Canadian experience.

First, because Canada’s flour supply is fortified with folic acid, plasma homocysteine level (determined primarily by folate status) is much less effective in the diagnostic work-up of suspected cobalamin deficiency. In a large population-based study, we established the